CGK012

CKG012 is an inhibitor for Wnt/βcatenin signaling pathway. CGK012 inhibits release of HMGB1 and transcription of β-catenin, exhibits attenuating activities against cecal ligation and puncture (CLP) -induced sepsis and multiple myeloma cancer[1][2].

Product Specifications

CAS Number

[2044497-76-7]

UNSPSC

12352005

Target

Wnt; β-catenin

Type

Reference compound

Related Pathways

Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/cgk012.html

Concentration

10mM

Purity

99.96

Solubility

DMSO : ≥ 25 mg/mL

Smiles

O=C(O[C@H]1CC2=CC(C=CC3=O)=C(O3)C=C2OC1(C)C)NC4CCCC4

Molecular Formula

C20H23NO5

Molecular Weight

357.40

References & Citations

[1]Park YJ, et al., Antiseptic Functions of CGK012 against HMGB1-Mediated Septic Responses. Int J Mol Sci. 2024 Mar 4;25 (5) :2976. |[2]Choi PJ, et al., Anti-proliferative activity of CGK012 against multiple myeloma cells via Wnt/β-catenin signaling attenuation. Leuk Res. 2017 Sep;60:103-108.